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The 2012 Nobel Prize in Medicine or Physiology recognizes the architects of two of the great
paradigm-shifting discoveries of the last half-century of biology. In experiments performed nearly
50 years apart, Gurdon and Yamanakamade feasible the reawakening of pluripotency inherent in all
cells and challenged forever our notions of cellular identity.In a shared accolade that was widely
anticipated, the Swedish Academy rec-
ognized Sir John Gurdon of the United
Kingdom and Shinya Yamanaka of Japan
for their demonstration that differentiated
somatic cells can be reverted, or reprog-
rammed, to an embryonic state. Their
momentous contributions have funda-
mentally shaped our understanding of
cellular differentiation and dedifferentia-
tion, ushered in powerful opportunities
for modeling human disease in vitro, and
brought personalized cellular and genetic
therapies closer to reality. Their work has
taught us to accept that cells are plastic
and malleable and can be engineered as
tools for research and novel medicines.
Indeed, these two scientists achieved
the seemingly impossible in cellular
alchemy, transforming the leaden state
of somatic tissues into the golden oppor-
tunity of pluripotent stem cells.
To understand the impact of the
discoveries by Gurdon and Yamanaka,
one must review a bit of scientific history
to appreciate the intellectual traditions
that have been so summarily altered.
Ever since Leeuwenhoek trained his
microscope on the earliest steps of
embryogenesis, scientists have marveled
at how a single-celled zygote can trans-
mogrify into complex multicellular fates
and organismal form. As one cell divides
to become two, then two to become
four, and so on, scientists have wondered
at what point do the cells became unequal
in their properties and in their destinies,and by what mechanisms? In 1885,
August Weismann published the theory
that development worked by ‘‘qualitative
divisions’’ among daughter cells, which
segregated subsets of heritable material
to specify their unique traits. In 1888, Wil-
helm Roux pricked and ablated one cell of
a two-cell frog embryo and observed
formation of a ‘‘half-embryo,’’ suggesting
that, even at the two-cell stage, the
embryonic blastomeres were nonequiva-
lent, an experiment consistent with the
notion of qualitative division. In 1892,
Hans Driesch challenged that interpreta-
tion when he microdissected and sepa-
rated sea urchin embryos at the two-cell
stage and observed formation of two
equivalent sea urchins, thereby extending
the notion of nuclear equivalence at least
to the two-cell stage. Later, Hans Spe-
mann tied tiny hairs from his daughter’s
head around early-stage newt embryos,
separating early blastomeres and ob-
serving formation of two normal newts,
albeit one smaller than the other, proving
developmental equivalence up to the
eight-cell stage. Spemann famously envi-
sioned but never technically realized
a ‘‘fantastical experiment’’ whereby the
nucleus of a highly differentiated cell
might be transplanted back to the egg to
test whether it would remain specialized
or would manifest embryonic potential.
Reporting precisely that experiment in
1952, Briggs and King showed that,
when nuclei were transplanted from the
blastula stage cells of a frog embryoCell 151, D(Rana pipiens), a point when cellular
specialization had already begun, a third
of reconstructed zygotes produced a
swimming tadpole (Briggs and King,
1952). Their subsequent nuclear trans-
plantation studies documented that cells
from the gastrula stage showed reduced
success, and ultimately, nuclei of the
endoderm of the tail bud stage generated
only abnormal embryos, thus suggesting
that cells lose the ability to support normal
embryonic development as development
and cell specialization progresses.
Working in the more pliable Xenopus
system, Gurdon diligently performed
thousands of nuclear transfers, confirm-
ing that the efficiency of generating devel-
opmentally normal frogs declined with
increasing maturity of donor cells. Most
importantly, however, he established
that normal development to adulthood
could be achieved by transfer of fully
differentiated nuclei from intestinal cells
of feeding-stage larvae (Gurdon, 1962;
Gurdon and Uehlinger, 1966). These
remarkable experiments established that
at least some highly differentiated cells re-
tained all relevant hereditary information
as the zygote and that cell specialization
need not entail the discarding of nuclear
material during cell specialization nor
any irreversible genetic alteration to the
cell. Gurdon’s profound contribution
represents the foundation of our current
assumptions about nuclear equivalence.
His bold and painstaking experiments
have stood the test of time and are theecember 7, 2012 ª2012 Elsevier Inc. 1151
intellectual foundation of the excitement
that has consumed the last 15 years of
stem cell biology.
Gurdon’s successful nuclear transfer
in the amphibian led to widespread
attempts in other organisms to produce
genetically identical animals through
nuclear transplantation, a process
dubbed ‘‘cloning.’’ Such attempts were
technically challenging due to the small
size of the mammalian egg and its sensi-
tivity to experimental manipulation. In
1983, McGrath and Solter reported
successful development of a nuclear
transplantation procedure in mice, allow-
ing them to observe a >90% frequency
of live births following transfer of a zygotic
nucleus into an enucleated zygote, which
proved their technical facility. However,
when they performed nuclear transfer
from cells at later stages, they observed
progressively lower efficiency and failed
in attempts at nuclear transplantation
from the eight-cell stage and inner cell
mass (McGrath and Solter, 1984). In
a statement that dissuaded many from
pursuing further attempts at cloning
mammals, they concluded that ‘‘reprog-
ramming after transfer into the zygote is
impossible in the mammalian embryo’’
and that ‘‘the cloning of mammals by
simple nuclear transfer is biologically
impossible’’ (McGrath and Solter, 1984).
Despite these admonitions, efforts con-
tinued, in part driven by the value to
animal husbandry of producing identical
herds of farm animals through cloning. In
the late 1980s and early 1990s, nuclear
transplantation of embryonic cells proved
successful in cloning numerous mam-
mals, including sheep, pigs, cows, mice,
and monkeys. In 1996, Campbell and Wil-
mut succeeded in deriving two cloned
sheep from a differentiated cell line estab-
lished from a 9-day-old embryo (Camp-
bell et al., 1996), and a year later they
achieved worldwide acclaim by success-
fully deriving a single sheep, ‘‘Dolly,’’ from
the mammary cells of an adult ewe (Wil-
mut et al., 1997). In their case, success
necessitated adaptations of the cell cycle
of the donor nucleus to better match that
of the recipient oocyte. These data
extended Gurdon’s principle of nuclear
equivalence for all somatic cells to fully
differentiated cells of an adult mammal,
an experiment that had implications far
beyond the scientific community.1152 Cell 151, December 7, 2012 ª2012 ElseA year after Dolly, the field was again
rocked by the successful establishment
in culture of human embryonic stem cells
(hESCs) by Jamie Thomson and col-
leagues (Thomson et al., 1998). The juxta-
position of these two major advances
suggested a compelling prospect:
perhaps the two techniques could be
melded together to isolate hESCs from
blastocysts generated by nuclear transfer
using donor nuclei from patients with
specific genetic diseases. With success,
such cells could be differentiated into
tissues affected by that disease to illumi-
nate disease mechanisms, or the gene
defects in the cells could be repaired,
generating normal hESCs and normal
derivative tissues for transplantation. In
a proof-of-principle experiment for just
such a potential therapeutic application,
Rudolf Jaenisch and I collaborated to
derive ESCs by nuclear transfer from cells
of mice with genetic immune deficiency
(Rideout et al., 2002). Our teams cor-
rected the responsible gene defect, differ-
entiated the repaired cells in vitro into
hematopoietic stem cells, and then
subsequently engrafted mice. The result-
ing mice showed partial restoration of B
and T cell lineages and immune function
as measured by serum levels of immuno-
globulin (Rideout et al., 2002). Lorenz
Studer’s group applied a similar strategy
to demonstrate production of dopami-
nergic neurons from stem cells made
from somatic cell nuclear transfer (ntES
cells), followed by transplantation to
relieve motor symptoms in a murine
model of Parkinson’s disease (Barberi
et al., 2003). Studer’s later experiments
demonstrated also that the lack of an
immune response of the input DA neurons
contributed to their more robust function,
establishing the value of generating
rejection-proof, autologous therapeutic
tissues from a patient’s own cells (Tabar
et al., 2008).
Though in principle, somatic cell
nuclear transplantation (SCNT) offered
a means of producing autologous tissues
for research and transplantation, in prac-
tice, the procedures were technically
cumbersome, labor intensive, and time
consuming, reducing their practicality.
Moreover, the approach raised the
specter that scientists might try to clone
human babies, which was never the inten-
tion of any credible practitioners of SCNT.vier Inc.Indeed, within the United States, the
manipulation of the human embryo en-
tailed by these procedures caused
tremendous controversy. Funding of
such research was prohibited by US law,
and President George W. Bush extended
funding restrictions to any newly created
hESC lines, effectively precluding a role
for the US National Institutes of Health in
fostering research in this arena. Programs
funded through private philanthropy,
like the Harvard Stem Cell Institute, or
through state government bonds, like
the California Institute for Regenerative
Medicine, sprung up to pursue the
compelling scientific possibilities of this
new field. Even with private or state fund-
ing, however, scientists garnered little
access to human oocytes needed for re-
programming, and efforts to reprogram
human nuclei in heterologous species
like the cow and pig met with abject
failure.
The legacy of Gurdon had established
the principle of conservation of the
genome during cellular differentiation.
His success with nuclear transfer estab-
lished that molecular machinery within
the egg cytoplasmwas sufficient to repro-
gram a somatic genome to a pluripotent
state. These early experiments compelled
scientists to envision strategies to purify
and characterize biochemical activities
from egg cytoplasm. Some hypothesized
a role for pluripotency factors like Oct4
and Nanog in reprogramming, but all
imagined the ultimate task to be daunting.
In 2004, in a review entitled ‘‘The First
Half-Century of Nuclear Transplantation,’’
Gurdon wrote: ‘‘We believe that the
remarkable reprogramming activity of
egg and oocyte cytoplasm will eventually
be understood in terms of identified mole-
cules, and it may well be possible to apply
the equivalent human molecules to
reprogram somatic cells, which would
have to be proliferated in vitro as are
embryonic stem cells (Gurdon and Byrne,
2003).’’ The challenge seemed infinitely
complex, and Gurdon surmised that ‘‘a
second half-century of nuclear transplan-
tation should identify the molecules and
mechanisms that achieve nuclear reprog-
ramming.’’
Given this daunting challenge, the
experiments of Shinya Yamanaka are all
the more remarkable. In the early years
of the last decade, Yamanaka was
Figure 1. Reprogramming Allows Derivation of Patient-Specific
Induced Pluripotent Stem Cells
Such cells provide a substrate for studies of disease mechanisms and path-
ogenesis; screening of small-molecule or protein therapeutics; and, through
directed differentiation, the production of medically valuable cell populations
like hematopoietic stem cells (HSCs) for therapeutic transplantation.establishing a growing repu-
tation in the stem cell com-
munity for his elucidations of
the role of factors like E-Ras
and Nanog in ESC pluripo-
tency. Knowing that experi-
mental fusion with hESCs
effectively reprogrammed
the somatic donor nucleus of
a differentiated cell (Cowan
et al., 2005), Yamanaka and
his graduate student Kazu-
toshi Takahashi compiled
a set of gene candidates that
might account for the pluripo-
tent nature of hESCs. Rather
than endeavor to painstak-
ingly purify the enzymatic
complexes responsible for
reprogramming by the egg
cytoplasm, Yamanaka hypo-
thesized that hemight change
the fate of somatic cells by
ectopic expression of tran-
scriptional regulators, DNA-
binding proteins that had
been shown in other systems
to induce fate changes (e.g.,
MyoD; Davis et al., 1987).
Among the many hundreds
of candidates that distinguishESCs from fibroblasts, Yamanaka winn-
owed the set to 24. Takahashi then intro-
duced all 24 candidate factors at once
into a culture of mouse embryonic fibro-
blasts that had been engineered to carry
a reporter gene active in pluripotent
stem cells. Remarkably, the experiment
worked, yielding cells that appeared
morphologically like ESCs, expressed
many of the expected markers of ESCs,
and showed the ability to differentiate
into cells from all three germ layers
in vitro and in chimeric mice. In a second
inspired experimental strategy, Takahashi
and Yamanaka repeated the experiments
multiple times with subsets of factors,
noting that failed experiments were most
informative for identifying the essential
core reprogramming factors. Ultimately,
they whittled down the list to the now
famous core Yamanaka factors: Oct4,
Sox2, KLF4, and c-Myc, which are alone
sufficient to revert a somatic cell to its
latent embryonic potential. They dubbed
their products ‘‘induced Pluripotent
Stem Cells,’’ now widely known as
iPS cells (iPSCs) (Takahashi and Yama-naka, 2006; see also Document S1,
available online, for Takahashi and
Yamanaka [2006] annotated by Konrad
Hochedlinger).
Though the first paper from Takahashi
and Yamanaka established the feasibility
of somatic cell reprogramming with a
small set of defined factors, further refine-
ments by his lab, as well as work by
Hochedlinger and Jaenisch, yielded
more faithfully reprogrammed cells and
proved that iPSCs are indeed the func-
tional equivalents of ESCs. Given the
robustness of the original observation,
numerous groups contributed to rapid
improvements in reprogramming tech-
nology. In just over a year after the
landmark reprogramming publication by
Takahashi and Yamanaka, Yamanaka’s
(Takahashi et al., 2007) and Thomson’s
group (Yu et al., 2007), as well as my
own (Park et al., 2008b), reported in late
2007 the successful reprogramming of
human cells. In a blindingly quick period
of time, the field turned its attention
away from SCNT and converged on this
new factor-based reprogramming tech-Cell 151, December 7,nology to exploit its practical
implications. We quickly
applied reprogramming to
patient-derived fibroblasts
and reported the first large
collection of disease-specific
iPSC lines for conditions as
diverse as Parkinson’s, dia-
betes, and primary immune
deficiency (Park et al.,
2008a). Because of those
early studies, hundreds of
labs around the globe have
embraced this facile tech-
nology to model and study
the basic mechanisms of
numerous human diseases
(as reviewed in Robinton and
Daley [2012]).
The Yamanaka experi-
ments have ushered in an
era of cellular alchemy. With
cellular pathology apparent
in vitro, numerous laborato-
ries are interrogating disease
mechanisms and testing
chemicals and proteins as
potential therapeutics to
reverse the abnormal cell
functions (Figure 1). Even
more ambitious attempts arebeing launched to treat genetic diseases
or acquired conditions of aging like
macular degeneration with derivatives of
iPSCs made from a patient’s own cells.
iPSCs can be entirely ‘‘self’’ or autologous
cells, which theoretically escape the risk
of immune rejection. Though this remains
to be proven through clinical trials, this
technology heralds an era during which
any patient’s cells represent the ingredi-
ents for tissue repair and regeneration.
In a second major proof-of-principle
experiment for the utility of customized
pluripotent stem cells, Jaenisch and
colleagues derived iPSCs frommice engi-
neered to develop sickle cell anemia by
virtue of expression of mutant human
hemoglobin genes. They corrected the
sickle globin gene defect, differentiated
the cells in vitro into hematopoietic stem
cells, and engrafted diseased recipients,
which were subsequently cured of their
condition (Hanna et al., 2007). This
strategy represents a platform whereby
dozens of genetic blood disorders could
be treated by a common method and
offers a glimpse of a future whereby2012 ª2012 Elsevier Inc. 1153
gene repair is coupled to cell replacement
therapy for a diversity of conditions.
Yamanaka’s bold experiment has
further stimulated a whole host of new
possibilities. If a small set of defined
factors can reprogram a specialized cell
back to pluripotency, what might stop
a small set of factors from converting
one specialized cell type into another?
Indeed, dozens of papers now report
using the Yamanaka method of screening
small libraries of transcription factors for
their capacity to transform one cell type
into another, and the literature is buzzing
with reports of cellular alchemy, whereby
fibroblasts or other starting cell types are
being converted into cardiomyocytes,
neurons, hepatocytes, blood, and beyond
(Vierbuchen and Wernig, 2011).
With such promise, key questions arise.
When will medicines emerge from these
Nobel-prize winning discoveries? The
answer to this query is a difficult one,
but given the rapid pace of adoption
of iPSCs into the research armamen-
tarium of so many labs, we might not be
surprised if drug trials and the first
cellular therapies emerge within the next
5 years. However, like any novel bio-
technology, we must be realistic in
concluding that two or three decades
may be necessary before the applications
of iPSCs inmedicine are fully appreciated.
In the meantime, intense research will
continue.
A second and more controversial ques-
tion asks whether there is an ongoing
need for research on hESCs. Some polit-
ical forces within the United States are
using the occasion of the Nobel Prize to
argue that research on human-embryo-
derived stem cells is now superfluous.
Such a perspective is founded on ideo-
logical and not scientific reasoning and
is not supported by experts in iPSC deri-
vation (Hyun et al., 2007). The discovery
of murine iPSCs by Yamanaka was
founded on decades of research that re-
vealed the molecular machinery respon-
sible for the pluripotent state of ESCs.
The culture conditions for human and
mouse ESCs are different, and knowledge
of the specific conditions for growing
hESCs was essential to the success of
deriving human iPSCs. Indeed, in my1154 Cell 151, December 7, 2012 ª2012 Elseown laboratory, our facility with deriving
human iPSCs was due in large part to
our experience deriving novel hESC lines.
Without our expertise in identifying the
morphology of hESCs and our facility
with maintenance of healthy hESC cul-
tures, we would not have been successful
deriving human iPSCs. Though research
on human iPSCs has exploded because
of the ease of reprogramming and the
power of its applications in medicine,
there remain numerous reasons why
research on hESCs must continue. There
has been a decade more experience
with hESCs than with human iPSCs, and
two clinical trials of cell products of
hESCs have already begun. We stand to
learn invaluable lessons about the proper-
ties of all pluripotent stem cell products
through these initial human clinical exper-
iments. Moreover, many basic questions
about the growth conditions of hESCs
remain to be answered, especially given
that mouse and human ESCs and iPSCs
differ in fundamental properties. How the
X chromosome functions in iPSCs and
differentiated products that might come
from iPSCs remains mysterious and will
likely be understood best in direct com-
parison to the function of the X chromo-
some during the derivation of new hESC
lines under new conditions.
Science progresses most efficiently
when all possible avenues of exploration
remain open. This year’s Nobel Prize
celebrates the creativity and brilliance
that can be achieved when scientists of
the highest caliber are free to ask bold
questions.
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